Mary Jande

810 total citations
23 papers, 599 citations indexed

About

Mary Jande is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mary Jande has authored 23 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pediatrics, Perinatology and Child Health, 7 papers in Pharmacology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mary Jande's work include Pharmacogenetics and Drug Metabolism (7 papers), Pharmaceutical Economics and Policy (4 papers) and Malaria Research and Control (4 papers). Mary Jande is often cited by papers focused on Pharmacogenetics and Drug Metabolism (7 papers), Pharmaceutical Economics and Policy (4 papers) and Malaria Research and Control (4 papers). Mary Jande collaborates with scholars based in Tanzania, Sweden and United Kingdom. Mary Jande's co-authors include Lars L. Gustafsson, Jane Sayi, Eleni Aklillu, Leif Bertilsson, Agneta Wennerholm, Amos Massele, Magnus Ingelman‐Sundberg, Rajaa A. Mirghani, Anders Rane and Cristina Rodríguez‐Antona and has published in prestigious journals such as PLoS ONE, Clinical Pharmacology & Therapeutics and European Journal of Clinical Pharmacology.

In The Last Decade

Mary Jande

22 papers receiving 573 citations

Peers

Countries citing papers authored by Mary Jande

Since Specialization

Citations

This map shows the geographic impact of Mary Jande's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Jande with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Jande more than expected).

Fields of papers citing papers by Mary Jande

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Jande. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Jande. The network helps show where Mary Jande may publish in the future.

Co-authorship network of co-authors of Mary Jande

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Jande. A scholar is included among the top collaborators of Mary Jande based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Jande. Mary Jande is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reducing neonatal mortality and respiratory distress syndrome associated with preterm birth: a scoping review on the impact of antenatal corticosteroids in low- and middle-income countries 2021 ·World Journal of Pediatrics ·(unknown), Mary Jande, (unknown), Benjamin Kamala, Deborah Dewey	13
2	Association between antenatal corticosteroid use and perinatal mortality among preterm births in hospitals in Tanzania 2021 ·PLoS ONE ·(unknown), Eveline T. Konje, Benjamin Kamala, (unknown), Semvua B. Kilonzo, (unknown), Karol J. Marwa, Mary Jande, Deborah Dewey	3
3	Prevalence and factor associated with over-the-counter use of antifungal agents’, in Mwanza City, Tanzania 2017 ·Tanzania journal of health research ·Martha F. Mushi, (unknown), Mary Jande, Mariam M. Mirambo, Stephen E. Mshana	8
4	Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications 2017 ·Expert Review of Clinical Pharmacology ·(unknown), Margaret Oluka, Eric M. Guantai, (unknown), Loice Achieng, (unknown), Mary Jande, Amos Massele, Brian Godman	37
5	Availability of prescribed medicines for elders at Sekou-Toure Regional Referral Hospital in Mwanza, Tanzania 2017 ·(unknown), (unknown), Mary Jande, (unknown)	1
6	Microbial contamination of traditional liquid herbal medicinal products marketed in Mwanza city: magnitude and risk factors 2016 ·Pan African Medical Journal ·(unknown), Karol J. Marwa, Jeremiah Seni, (unknown), Vitus Silago, Stephen E. Mshana, Mary Jande	14
7	Public Awareness and Identification of Counterfeit Drugs in Tanzania: A View on Antimalarial Drugs 2016 ·Advances in Public Health ·(unknown), Mary Jande, Anthony Cuthbert Liwa, (unknown), Karol J. Marwa	14
8	SY03-1-3 * ISAM FELLOWSHIP PREVALENCE OF HIV INFECTION AMONG THE OVER 18 YEAR OLD SUBSTANCE ABUSERS IN MWANZA URBAN, TANZANIA 2014 ·Alcohol and Alcoholism ·(unknown), (unknown), Samuel Kalluvya, Mary Jande, Charles Riziki Majinge, Saidi Kapiga, (unknown)	2
9	Community Awareness of Adverse Effects of Nonsteroidal Anti-inflammatory Drugs in Ilala Municipality, Dar es Salaam 2013 ·Mary Jande, (unknown), Anthony Cuthbert Liwa, (unknown), (unknown)	3
10	Assessment of Patient Satisfaction with Pharmaceutical Services in Hospital Pharmacies in Dar es Salaam, Tanzania 2013 ·Mary Jande, Anthony Cuthbert Liwa, (unknown), (unknown)	10
11	The Prevalence of Substance Use among Psychiatric Patients: The Case Study of Bugando Medical Centre, Mwanza (Northern Tanzania) 2011 ·Substance Abuse ·(unknown), David M. Ndetei, Mary Jande, Rodrick Kabangila	27
12	4β-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians 2008 ·Pharmacogenetics and Genomics ·Ulf Diczfalusy, Jun Miura, Hyung‐Keun Roh, Rajaa A. Mirghani, Jane Sayi, Hanna Larsson, Karl Bodin, (unknown), Mary Jande, (unknown), Eleni Aklillu, Lars L. Gustafsson, Leif Bertilsson	128
13	Quality of antiretroviral drugs, stavudine and indinavir capsules available in the Tanzanian market 2007 ·(unknown), Olipa Ngassapa, Jane Sayi, Mary Jande, Zameer Mohamed	1
14	CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir 2007 ·Clinical Pharmacology & Therapeutics ·Filip Josephson, (unknown), Mohamed Janabi, Jane Sayi, Eleni Aklillu, Mary Jande, (unknown), Jürgen Burhenne, Ylva Böttiger, Lars L. Gustafsson, Walter E. Haefeli, Leif Bertilsson	48
15	CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population 2006 ·Pharmacogenetics and Genomics ·Rajaa A. Mirghani, Jane Sayi, Eleni Aklillu, (unknown), Mary Jande, Agneta Wennerholm, Jaran Eriksen, Virginie M.M. Herben, Barry Jones, Lars L. Gustafsson, Leif Bertilsson	63
16	Identification and phenotype characterization of two haplotypes causing different enzymatic capacity in fetal livers 2005 ·Clinical Pharmacology & Therapeutics ·Cristina Rodríguez‐Antona, Mary Jande, Anders Rane, Magnus Ingelman‐Sundberg	46
17	Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans 2005 ·European Journal of Clinical Pharmacology ·Tashinga E. Bapiro, Jane Sayi, Julia A. Hasler, Mary Jande, (unknown), (unknown), Collen Masimirembwa	32
18	Decreased capacity for debrisoquine metabolism among black Tanzanians 1999 ·Pharmacogenetics ·Agneta Wennerholm, Inger Johansson, Amos Massele, Mary Jande, Christina Alm, (unknown), Marja‐Liisa Dahl, Magnus Ingelman‐Sundberg, Leif Bertilsson, Lars L. Gustafsson	51
19	Decreased capacity for debrisoquine metabolism among black Tanzanians 1999 ·Pharmacogenetics and Genomics ·Agneta Wennerholm, Inger Johansson, Amos Massele, Mary Jande, Christina Alm, (unknown), Marja‐Liisa Dahl, Magnus Ingelman‐Sundberg, Leif Bertilsson, Lars L. Gustafsson	0
20	Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype* 1998 ·Clinical Pharmacology & Therapeutics ·(unknown), Amos Massele, Mary Jande, Christina Alm, Gunnel Tybring, Yakoub Aden Abdi, Agneta Wennerholm, (unknown), Marja-Liisa Dahl, Leif Bertilsson, Lars L. Gustafsson	75

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact